4-methyl-2-(1-methylethoxy)benzenamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methyl-2-(1-methylethoxy)benzenamine
• 英文别名: 2-isopropoxy-4-methylaniline；3-isopropoxy-4-aminotoluene；4-Methyl-2-(propan-2-yloxy)aniline；4-methyl-2-propan-2-yloxyaniline
• 化学式: C₁₀H₁₅NO
• 分子量: 165.235
• InChiKey: YKMNQNXYSAAQGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-2-(1-methylethoxy)benzenamine 在 N2 、 copper(I) bromide 、 sodium nitrite 作用下， 以 正己烷 、 硫酸 、 水 、 乙酸乙酯 为溶剂， 以3.59 g (18%)的产率得到3-isopropoxy-4-bromotoluene
  参考文献：
  名称：

  Branched alkoxy-subsituted 2-aminopyridines

  摘要：

  本发明涉及式1中R1、R2、R3和R4如规范中定义的6-苯基吡啶-2-胺衍生物，其具有作为一氧化氮合酶（NOS）抑制剂的活性，以及含有它们的药物组合物，并用于治疗和预防中枢神经系统和其他疾病。

  公开号：

  US20020022642A1
• 作为产物：
  描述：

  5-methyl-1-(1-methylethoxy)-2-nitrobenzene 、 6-硝基间甲酚 在 palladium on charcoal 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙醚 、 乙腈 为溶剂， 生成 4-methyl-2-(1-methylethoxy)benzenamine
  参考文献：
  名称：

  Novel

  摘要：

  描述了一种新型N-(取代苯基)-5-(取代2,5-二甲基苯氧基)-2,2-二甲基戊内酰胺，可用于预防胆固醇的肠道吸收，并增加高密度脂蛋白（HDL）胆固醇，以及新型药物组合物和使用方法，以及其制备工艺。

  公开号：

  US04882357A1

文献信息

• Aryl carbonyl derivatives as therapeutic agents
  申请人：——

  公开号：US20040122235A1

  公开（公告）日：2004-06-24

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，其是葡萄糖激酶的激活剂，可用于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Polisetti Dharma Rao

  公开号：US20110301158A1

  公开（公告）日：2011-12-08

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，它们是葡萄糖激酶的活化剂，可能有助于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst
  申请人：L'OREAL

  公开号：US10251827B2

  公开（公告）日：2019-04-09

  The invention relates to a process for dyeing keratin fibers, comprising the use of one or more metal catalysts and of a composition (A) comprising: —one or more oxidizing agents, and —at least one monoaminobenzene of formula (I), or an addition salt or solvate thereof in which the radicals R1 to R5 represent, independently of each other: a hydrogen atom; a halogen atom, a C1-C6 alkyl radical, a C1-C6 alkoxy radical, a carboxylic radical (—COOH), a sulfonic radical (—S03 H); two of the adjacent radicals R1 to R5 possibly forming, with the carbon atoms that bear them, a saturated or unsaturated 5- to 7-membered ring, optionally comprising from 1 to 2 heteroatoms, preferably oxygen, the said ring being optionally fused with a saturated or unsaturated 5- to 6-membered ring; on condition that at least one of the radicals R1 to R5 represents an optionally substituted alkoxy radical and preferably at least one of the other radicals R1 to R5 is a hydrogen atom.

  本发明涉及一种角蛋白纤维染色工艺，包括使用一种或多种金属催化剂和一种组合物（A），组合物（A）包括： -一种或多种氧化剂，和 -至少一种式（I）的单胺苯，或其加成盐或溶液，其中自由基 R1 至 R5 各自代表：氢原子、卤素原子、C1-C6 烷基、C1-C6 烷氧基、羧基 (-COOH)、磺酸基 (-S03 H)；R1 至 R5 中相邻的两个基团可与含有它们的碳原子形成饱和或不饱和的 5 至 7 元环，可选择包含 1 至 2 个杂原子，最好是氧，所述环可选择与饱和或不饱和的 5 至 6 元环融合；条件是 R1 至 R5 自由基中至少有一个代表任选取代的烷氧基，且 R1 至 R5 自由基中至少有一个是氢原子。
• Pyrropyrimidine compounds as MNKs inhibitors
  申请人：LIFEARC

  公开号：US10604524B2

  公开（公告）日：2020-03-31

  The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R1 is selected from H and CO—NR8R9, wherein R8 and R9 are each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more R12 groups, and said heterocycloalkyl is optionally substituted by R10 or R12; or R8 and R9 are linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from R10 and (CH2)mR12; R2 is selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more R12 groups; R3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z1, Z2, Z3 and Z4 are all C; R4, R5, R6 and R7 are each independently selected from H, alkyl, CN, NO2, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z1, Z3 and Z4 are all C, Z2 is N, R5 is absent and R4, R6 and R7 are as defined above; or Z1, Z3 and Z4 are all C, Z1 is N, R4 is absent and R5, R6 and R7 are as defined above; each R10 and R11 is independently alkyl; each R12 is independently selected from CO2R10, COOH, OH, alkoxy, haloalkyl, NH2, NHR10, NR10R11, heteroaryl and heterocycloalkyl; R13 is H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

  本发明涉及式 I 的化合物或其药学上可接受的盐或酯，其中：R1选自H和CO-NR8R9，其中R8和R9各自独立地选自H、烷基、环烷基和单环或双环杂环烷基，其中所述烷基任选被一个或多个R12基团取代，所述杂环烷基任选被R10或R12取代；或 R8 和 R9 与所连接的氮相连，形成杂环烷基，该杂环烷基可选择含有一个或多个额外的杂原子，并可选择被一个或多个选自 R10 和 (CH2)mR12 的基团取代； R2 选自 H 和烷基，其中所述烷基可选择被一个或多个 R12 基团取代；R3选自烷基、环烷基和杂环烷基，其中每个环烷基可任选被卤代、OH或烷氧基取代；Z1、Z2、Z3和Z4均为C；R4、R5、R6和R7各自独立选自H、烷基、CN、NO2、OH、烷氧基、NHCO-烷基、卤代和卤代烷基；或Z1、Z3和Z4均为C，Z2为N，R5不存在，R4、R6和R7如上定义；或 Z1、Z3 和 Z4 均为 C，Z1 为 N，R4 不存在，R5、R6 和 R7 如上所定义；每个 R10 和 R11 独立为烷基；每个 R12 独立选自 CO2R10、COOH、OH、烷氧基、卤代烷基、NH2、NHR10、NR10R11、杂芳基和杂环烷基；R13 为 H 或卤代。进一步的方面涉及所述化合物的药物组合物和治疗用途，用于治疗细胞生长、增殖和/或存活失控的疾病、不适当的细胞免疫反应、不适当的细胞炎症反应或神经退行性疾病，优选牛磺酸病，更优选阿尔茨海默病。
• Reduction of nitrotoluenes in supercritical isopropanol over Al2O3 in a flow reactor
  作者：V. P. Sivcev、D. V. Korchagina、K. P. Volcho、N. F. Salakhutdinov、V. I. Anikeev

  DOI：10.1134/s0036024415020314

  日期：2015.2

  The reduction of o-, m-, and p-nitrotoluenes in supercritical isopropanol over Al2O3 in a flow reactor is studied. It is shown that corresponding toluidines are major reaction products. Aromatic ring alkoxylation and N-alkylation products make a considerable contribution to the composition of reaction mixtures.